Go to ...

New York Journal

RSS Feed

December 16, 2017

Medical & Health: Biotechnology

RowAnalytics, Martinos Center & Envision Genomics Create GIRO Health, a New Flagship Open Initiative in Precision Medicine

Cambridge, MA, December 07, 2017 –(PR.com)– RowAnalytics Ltd., the Martinos Center for Biomedical Imaging (Martinos Center) and Envision Genomics Inc. today announced that they are combining their world leading technologies and expertise with IBM Power servers, to create a new, open initiative in precision medicine, GIRO Health. This initiative will accelerate understanding of the biology

Making Artificial Intelligence Practical for Healthcare Marketers

Summit, NJ, December 06, 2017 –(PR.com)– Arteric is a healthcare digital marketing agency that’s been demystifying leading-edge technology and making it practical for healthcare marketers for two decades. On December 6, Arteric’s Hans Kaspersetz continued this effort when he explained how to apply artificial intelligence (AI) to uncover hidden market insights at Medical Marketing and

RegenLab Issued New US Patent for Platelet Rich Plasma Kits

New York, NY, December 05, 2017 –(PR.com)– On December 5, 2017, RegenLab USA LLC (“RegenLab”) alleges to have obtained US Pat. No. 9,833,478 (“the ‘478 patent”), with claims directed to medical separator systems for the preparation of platelet rich plasma. Since November 2016, RegenLab has been involved in patent litigation with Israeli manufacturer Estar Technologies

RowAnalytics Cements Its North American Presence with a New Office in Boston – to Introduce a Radically Different Approach to Precision Medicine

Cambridge, MA, November 30, 2017 –(PR.com)– RowAnalytics today announced that it has established its presence in North America with an office in Cambridge, MA to further collaborative research in precision medicine with the world’s leading academic, clinical and biotechnology organizations. Located in the heart of Kendall Square, which offers an inspirational rich history in biotech

Perthera and ZERO Announce the Decode Your Prostate Cancer Program

McLean, VA, November 28, 2017 –(PR.com)– Perthera, Inc., the leading Therapeutics Intelligence Company™, has announced its partnership with ZERO, the leading nonprofit prostate cancer advocacy group in the USA, to form and launch the nationwide Decode Your Prostate Cancer program aimed to provide each prostate cancer patient with therapeutic treatment options precisely matched to their

No Insight Left Behind. Guiding Healthcare Marketers to Wise Decisions About Artificial Intelligence.

Summit, NJ, November 27, 2017 –(PR.com)– Arteric is a healthcare digital marketing agency that continually shares its knowledge with the healthcare marketing community. That effort continues at the second annual MedDev eMarketing Summit in Philadelphia on November 29. Hans Kaspersetz, Arteric’s Chief Strategist and Technologist, will present a seminar titled “Artificial Intelligence – Super Hearing

Stool Bank in Asia Welcomes New Scientist

New York, NY, November 16, 2017 –(PR.com)– The Asia Microbiota Bank Welcomes New Scientific Team Member The Asia Microbiota Bank (AMB), headquartered in Hong Kong, is pleased to announce they have been joined by a new scientific team member, Subramanya Rao, PhD. As an expert microbiologist and bioinformatician, Dr. Rao will lead the laboratory production

Perimeter Medical Imaging Appoints Dr. Franklyn Prendergast to Board of Directors

Toronto, Canada, November 16, 2017 –(PR.com)– Perimeter Medical Imaging Inc., a developer of real time imaging systems for in-surgery tissue assessment, is pleased to announce that Dr. Franklyn Prendergast, will be joining Perimeter’s Board of Directors. Dr. Prendergast spent his entire professional career at Mayo Clinic in Rochester, MN. He retired from Mayo in December

Cellenkos Inc. Enters Regulatory T-Cell Platform Research Collaboration with MD Anderson

Houston, TX, November 15, 2017 –(PR.com)– Cellenkos Inc. has announced a multi-year collaboration with The University of Texas MD Anderson Cancer Center focused on development of cord blood regulatory T cell (CB TREG) therapeutics for treatment of autoimmune disease and inflammatory disorders. As part of this collaboration, Cellenkos Inc. will fund up to 10,000,000 USD

The European Medicines Agency Accepts Marketing Authorisation Application for Intrarosa for the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Quebec, Canada, November 13, 2017 –(PR.com)– Endoceutics Inc., a private Quebec City based biopharma company, today announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product IntrarosaTM, intended for the treatment of vulvar and vaginal atrophy in postmenopausal women.

Older Posts››